While Standard BioTools Inc has overperformed by 0.84%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LAB fell by -31.43%, with highs and lows ranging from $2.41 to $0.92, whereas the simple moving average fell by -19.97% in the last 200 days.
On February 27, 2025, KeyBanc Capital Markets Downgraded Standard BioTools Inc (NASDAQ: LAB) to Sector Weight. A report published by TD Cowen on April 16, 2024, Initiated its previous ‘Buy’ rating for LAB. Jefferies also rated LAB shares as ‘Buy’, setting a target price of $3.25 on the company’s shares in an initiating report dated April 04, 2024. KeyBanc Capital Markets Initiated an Overweight rating on July 12, 2023, and assigned a price target of $4.
Analysis of Standard BioTools Inc (LAB)
Further, the quarter-over-quarter decrease in sales is -10.42%, showing a negative trend in the upcoming months.
To gain a thorough understanding of Standard BioTools Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -25.73% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.37, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and LAB is recording an average volume of 1.72M. On a monthly basis, the volatility of the stock is set at 8.22%, whereas on a weekly basis, it is put at 7.95%, with a loss of -2.44% over the past seven days. Furthermore, long-term investors anticipate a median target price of $2.38, showing growth from the present price of $1.2, which can serve as yet another indication of whether LAB is worth investing in or should be passed over.
How Do You Analyze Standard BioTools Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.18%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 72.28% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
LAB shares are owned by institutional investors to the tune of 72.28% at present.
